Logo image of SLGL

SOL-GEL TECHNOLOGIES LTD (SLGL) Stock Fundamental Analysis

NASDAQ:SLGL - Nasdaq - IL0011417206 - Common Stock - Currency: USD

7.47  -0.2 (-2.6%)

Fundamental Rating

4

Overall SLGL gets a fundamental rating of 4 out of 10. We evaluated SLGL against 198 industry peers in the Pharmaceuticals industry. SLGL has a great financial health rating, but its profitability evaluates not so good. SLGL is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

SLGL had negative earnings in the past year.
In the past year SLGL has reported a negative cash flow from operations.
SLGL had negative earnings in 4 of the past 5 years.
In the past 5 years SLGL always reported negative operating cash flow.
SLGL Yearly Net Income VS EBIT VS OCF VS FCFSLGL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -10M -20M -30M

1.2 Ratios

Looking at the Return On Assets, with a value of -35.51%, SLGL is in line with its industry, outperforming 47.47% of the companies in the same industry.
The Return On Equity of SLGL (-42.73%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -35.51%
ROE -42.73%
ROIC N/A
ROA(3y)-29.16%
ROA(5y)-35.43%
ROE(3y)-33.35%
ROE(5y)-40.91%
ROIC(3y)N/A
ROIC(5y)N/A
SLGL Yearly ROA, ROE, ROICSLGL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50 -50 -100 -150 -200

1.3 Margins

SLGL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SLGL Yearly Profit, Operating, Gross MarginsSLGL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -5K -10K -15K -20K -25K

More info and screens

8

2. Health

2.1 Basic Checks

SLGL does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SLGL has more shares outstanding
SLGL has more shares outstanding than it did 5 years ago.
SLGL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SLGL Yearly Shares OutstandingSLGL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 500K 1M 1.5M 2M 2.5M
SLGL Yearly Total Debt VS Total AssetsSLGL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

2.2 Solvency

An Altman-Z score of 9.87 indicates that SLGL is not in any danger for bankruptcy at the moment.
SLGL has a Altman-Z score of 9.87. This is amongst the best in the industry. SLGL outperforms 87.88% of its industry peers.
There is no outstanding debt for SLGL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 9.87
ROIC/WACCN/A
WACC9.02%
SLGL Yearly LT Debt VS Equity VS FCFSLGL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M -40M 60M

2.3 Liquidity

SLGL has a Current Ratio of 7.36. This indicates that SLGL is financially healthy and has no problem in meeting its short term obligations.
SLGL has a Current ratio of 7.36. This is in the better half of the industry: SLGL outperforms 79.29% of its industry peers.
A Quick Ratio of 7.36 indicates that SLGL has no problem at all paying its short term obligations.
The Quick ratio of SLGL (7.36) is better than 79.80% of its industry peers.
Industry RankSector Rank
Current Ratio 7.36
Quick Ratio 7.36
SLGL Yearly Current Assets VS Current LiabilitesSLGL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 68.81% over the past year.
SLGL shows a strong growth in Revenue. In the last year, the Revenue has grown by 873.15%.
SLGL shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 64.25% yearly.
EPS 1Y (TTM)68.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95.24%
Revenue 1Y (TTM)873.15%
Revenue growth 3Y-43.83%
Revenue growth 5Y64.25%
Sales Q2Q%2416.9%

3.2 Future

SLGL is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.10% yearly.
SLGL is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 94.55% yearly.
EPS Next Y97.17%
EPS Next 2Y39.99%
EPS Next 3Y25.4%
EPS Next 5Y15.1%
Revenue Next Year870.39%
Revenue Next 2Y137.02%
Revenue Next 3Y94.6%
Revenue Next 5Y94.55%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
SLGL Yearly Revenue VS EstimatesSLGL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 20M 40M 60M 80M
SLGL Yearly EPS VS EstimatesSLGL Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -10 -20 -30

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

SLGL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SLGL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SLGL Price Earnings VS Forward Price EarningsSLGL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SLGL Per share dataSLGL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

SLGL's earnings are expected to grow with 25.40% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.99%
EPS Next 3Y25.4%

More info and screens

0

5. Dividend

5.1 Amount

SLGL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SOL-GEL TECHNOLOGIES LTD

NASDAQ:SLGL (5/16/2025, 8:22:30 PM)

7.47

-0.2 (-2.6%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-25 2025-03-25/amc
Earnings (Next)05-19 2025-05-19
Inst Owners18.81%
Inst Owner Change1.42%
Ins Owners0.31%
Ins Owner ChangeN/A
Market Cap208.11M
Analysts82.86
Price TargetN/A
Short Float %N/A
Short Ratio0.66
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)41.99%
Min EPS beat(2)-50.33%
Max EPS beat(2)134.31%
EPS beat(4)3
Avg EPS beat(4)24.81%
Min EPS beat(4)-50.33%
Max EPS beat(4)134.31%
EPS beat(8)4
Avg EPS beat(8)-21.82%
EPS beat(12)8
Avg EPS beat(12)12.21%
EPS beat(16)11
Avg EPS beat(16)12.65%
Revenue beat(2)1
Avg Revenue beat(2)170.27%
Min Revenue beat(2)-64.86%
Max Revenue beat(2)405.4%
Revenue beat(4)2
Avg Revenue beat(4)83.63%
Min Revenue beat(4)-69.84%
Max Revenue beat(4)405.4%
Revenue beat(8)3
Avg Revenue beat(8)17.65%
Revenue beat(12)5
Avg Revenue beat(12)3.79%
Revenue beat(16)7
Avg Revenue beat(16)-2.56%
PT rev (1m)20%
PT rev (3m)20%
EPS NQ rev (1m)-900%
EPS NQ rev (3m)-900%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 31.73
P/FCF N/A
P/OCF N/A
P/B 5.96
P/tB 5.96
EV/EBITDA N/A
EPS(TTM)-3.4
EYN/A
EPS(NY)-0.41
Fwd EYN/A
FCF(TTM)-0.61
FCFYN/A
OCF(TTM)-0.61
OCFYN/A
SpS0.24
BVpS1.25
TBVpS1.25
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -35.51%
ROE -42.73%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-29.16%
ROA(5y)-35.43%
ROE(3y)-33.35%
ROE(5y)-40.91%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.16
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.36
Quick Ratio 7.36
Altman-Z 9.87
F-Score4
WACC9.02%
ROIC/WACCN/A
Cap/Depr(3y)28.48%
Cap/Depr(5y)40.05%
Cap/Sales(3y)4.48%
Cap/Sales(5y)4.24%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)68.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95.24%
EPS Next Y97.17%
EPS Next 2Y39.99%
EPS Next 3Y25.4%
EPS Next 5Y15.1%
Revenue 1Y (TTM)873.15%
Revenue growth 3Y-43.83%
Revenue growth 5Y64.25%
Sales Q2Q%2416.9%
Revenue Next Year870.39%
Revenue Next 2Y137.02%
Revenue Next 3Y94.6%
Revenue Next 5Y94.55%
EBIT growth 1Y38.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-459.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-495%
OCF growth 3YN/A
OCF growth 5YN/A